Lucid Diagnostics (NASDAQ:LUCD - Get Free Report) will post its quarterly earnings results before the market opens on Monday, May 13th. Persons interested in listening to the company's earnings conference call can do so using this link.
Lucid Diagnostics (NASDAQ:LUCD - Get Free Report) last issued its quarterly earnings results on Tuesday, March 26th. The company reported ($0.26) earnings per share (EPS) for the quarter. The company had revenue of $1.04 million during the quarter. Lucid Diagnostics had a negative net margin of 2,169.07% and a negative return on equity of 901.79%. During the same period in the prior year, the business posted ($0.22) EPS.
Lucid Diagnostics Stock Up 11.9 %
Shares of NASDAQ:LUCD traded up $0.11 during trading on Monday, reaching $1.04. 475,964 shares of the company traded hands, compared to its average volume of 161,720. The firm has a market capitalization of $51.77 million, a PE ratio of -0.82 and a beta of 1.48. Lucid Diagnostics has a 52 week low of $0.63 and a 52 week high of $1.85. The company's 50 day moving average is $0.99 and its two-hundred day moving average is $1.23.
Analysts Set New Price Targets
LUCD has been the topic of a number of analyst reports. Needham & Company LLC reiterated a "buy" rating and set a $2.50 price objective on shares of Lucid Diagnostics in a research note on Friday, April 12th. Cantor Fitzgerald reduced their price target on shares of Lucid Diagnostics from $3.80 to $3.00 and set an "overweight" rating on the stock in a research report on Wednesday, March 27th.
Read Our Latest Report on LUCD
Lucid Diagnostics Company Profile
(
Get Free Report)
Lucid Diagnostics Inc, a commercial-stage medical diagnostics technology company, focuses on patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma in the United States. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients.
See Also
Before you consider Lucid Diagnostics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lucid Diagnostics wasn't on the list.
While Lucid Diagnostics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
